Related Experiment Video

Updated: Jun 21, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.0K

Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity

Meng-Ju Wu1,2,3,4, Hiroshi Kondo1,2,3,4, Ashwin V Kammula1,3,4

  • 1Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston MA, USA.

Science (New York, N.Y.)
|July 11, 2024
PubMed

Insights

Mutant Isocitrate dehydrogenase 1 (mIDH1) suppresses antitumor immunity by silencing the CGAS sensor. Inhibiting mIDH1 restores CGAS, activating immune responses against cancer.

Area of Science:

  • Oncology
  • Immunology
  • Epigenetics

Background:

  • Isocitrate dehydrogenase 1 (IDH1) mutations are common in human cancers.
  • Mutant IDH1 (mIDH1) produces (R)-2-hydroxyglutarate, affecting epigenetic enzymes.
  • IDH1-mutant tumors often exhibit T cell exclusion, hindering antitumor immunity.

Purpose of the Study:

  • To define a cell-autonomous mechanism of mIDH1-driven immune evasion.
  • To investigate how mIDH1 impacts innate immune signaling pathways.
  • To explore the therapeutic potential of mIDH1 inhibition on antitumor immunity.

Main Methods:

  • Analysis of IDH1-mutant solid tumors.
  • Investigating the role of the CGAS sensor in immune evasion.
  • Assessing the effects of mIDH1 inhibition on DNA methylation and gene expression.
  • Studying the activation of cGAS by dsDNA from transposable elements (TEs).

Main Results:

  • IDH1-mutant tumors exhibit hypermethylation and silencing of the CGAS sensor, impairing innate immunity.
  • mIDH1 inhibition leads to DNA demethylation and derepression of CGAS and TEs.
  • dsDNA from TE-reverse transcriptase (TE-RT) activates cGAS, mimicking viral infection.
  • This activation triggers an antitumor immune response.

Conclusions:

  • mIDH1 epigenetically suppresses innate immunity by silencing CGAS.
  • Endogenous reverse transcriptase (RT) activity is linked to the mechanism of action of an FDA-approved oncology drug.
  • Restoring CGAS signaling via mIDH1 inhibition enhances antitumor immunity.

More Related Videos

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

306
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.0K